Jefferies rates Parexel at buy

Parexel International Corp. was given a buy rating by Jefferies & Co., Inc. analyst David Windley on news that the company is outperforming its top competitors on business wins, with net bookings up 89% and a net book-to-bill of 1.85. Parexel reported earnings per share of $0.31 on service revenues of $169.5 million for the fourth quarter of 2006, compared to the analyst's estimate of $0.28 per share on service revenues of $162.9 million. Shares of the Waltham, Mass.-based biopharmaceutical company were up $1.93, or 6.81%, at $30.27, on volume of 689,185 shares versus the three-month running average of 246,761 shares. (Nasdaq: PRXL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.